Analysis on Rationality of Ertapenem in 300 Inpatients

SHANG Chen; SHUAI Yuan; YING Yingqiu; YANG Li; ZHAO Rongsheng

doi:10.14009/j.issn.1672-2124.2021.04.022

您当前的位置：

首页 >

文章列表页 >

Analysis on Rationality of Ertapenem in 300 Inpatients

更新时间：2022-10-08

- Analysis on Rationality of Ertapenem in 300 Inpatients
- Vol. 21, Issue 4, Pages: 478-480(2021)
- 作者机构：
  
  北京大学第三医院药剂科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.04.022
  CLC： R969.3
- Published：2021，
扫描看全文
[1]尚晨,帅瑗,应颖秋,杨丽,赵荣生.300例住院患者厄他培南应用合理性分析[J].中国医院用药评价与分析,2021,21(04):478-480+484.

SHANG Chen, SHUAI Yuan, YING Yingqiu, et al. Analysis on Rationality of Ertapenem in 300 Inpatients. [J]. 21(4):478-480(2021)
[1]尚晨,帅瑗,应颖秋,杨丽,赵荣生.300例住院患者厄他培南应用合理性分析[J].中国医院用药评价与分析,2021,21(04):478-480+484. DOI： 10.14009/j.issn.1672-2124.2021.04.022.

SHANG Chen, SHUAI Yuan, YING Yingqiu, et al. Analysis on Rationality of Ertapenem in 300 Inpatients. [J]. 21(4):478-480(2021) DOI： 10.14009/j.issn.1672-2124.2021.04.022.

摘要

目的:了解北京大学第三医院（以下简称"我院"）住院患者厄他培南使用情况

评价用药合理性并分析原因。方法:采用回顾性研究设计、分层随机抽样法

获取2018年4月至2019年3月我院使用厄他培南的住院患者病历300份

基于《抗菌药物临床应用指导原则（2015年版）》、相关指南及专家共识

对患者使用厄他培南的适应证、微生物送检情况、用法与用量以及联合用药等方面进行统计分析

评价用药合理性及其相关影响因素。结果:使用厄他培南的300例住院患者中

围手术期预防用药42例（占14.00%）;治疗用药258例（占86.00%）

其中208例接受了微生物检查

治疗用药前微生物送检111例（占微生物送检总病例数的53.37%）。合理用药238例

用药合理率为79.33%;不合理用药主要表现为抗菌药物用药起点过高、用药疗程过长以及联合用药不适宜等。影响厄他培南用药合理性的因素包括是否有临床药师干预（P <0.05）和科室类别（P <0.001）。结论:我院厄他培南的使用仍存在不合理现象

需进一步加强干预管理

促进厄他培南在临床的合理应用。

Abstract

OBJECTIVE: To investigate the application of ertapenem in inpatients of Peking University Third Hospital（ hereinafter referred to as "our hospital"）

so as to evaluate the rationality of medication and analyze the reasons. METHODS: The retrospective study method were used to obtain 300 medical records of inpatients receiving ertapenem in our hospital from Apr. 2018 to Mar. 2019. Based on the Guidelines for Clinical Application of Antibiotics（ 2015 Edition）

relevant guidelines and expert consensus

statistical analysis was performed on indications

microbiological examination submission

usage and dosage

and drug combination. Rationality of medication and its related influencing factors were evaluated. RESULTS: Among the 300 inpatients receiving ertampenem

42 cases（ 14. 00%） received perioperative prophylactic drugs. There were 258 cases（ 86. 00%） of therapeutic drugs

among which 208 cases received microbiological examination

and 111 cases（ 53. 37% of the total number of microbiological examination） were submitted for microbiological examination before therapeutic drugs. There were 238 cases of rational drug application

with the rational rate of 79. 33%. The main manifestations of irrational drug application were high starting point of antibiotics

long duration of treatment and inappropriate drug combination. Factors influencing the application rationality of ertapenem included the clinical pharmacist intervention（ P < 0. 05） and department types（ P< 0. 001）. CONCLUSIONS: The application of ertapenem in our hospital is still irrational

intervention management needs to be further strengthened to promote the rational application of ertapenem in clinic.

关键词

厄他培南应用评价住院患者

Keywords

ErtapenemApplication evaluationInpatients

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Analysis on Application of Prescription Pre-Review System on Medical Orders with Overdose Oral Drugs in Central Pharmacy

Investigation and Analysis of Clinical Application of Human Albumin Injection in Inpatients of Beijing Hospital from 2019 to 2020

Application of Antidepressant Drugs in 1554 Inpatients with Depressive Disorder

Intervention Effects of Application of Proton Pump Inhibitors in Inpatients by Clinical Pharmacists

Analysis of Atomization Inhalation Medication for Inpatients in A Grade Ⅲ Level A Hospital

Related Author

HE Jun

MAO Min

YIN Limei

LIAN Wenwen

YAN Yu

LIU Nannan

李朗

杨子贤

Related Institution

Dept. of Pharmacy, China-Japan Friendship Hospital

Beijing Hospital

Dept. of Pharmaceutical Affairs,Beijing Anding Hospital, Capital Medical University, the National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders

Advanced Innovation Center for Human Brain Protection, Capital Medical University

Dept.of Pharmacy,Third People’s Hospital of Hechi

⁰